seekingalpha.com
Kestra Medical Technologies, Ltd. (KMTS) Q3 2026 Earnings Call Transcript
Kestra Medical Technologies, Ltd. (KMTS) Q3 2026 Earnings Call Transcript
KMTSKMTSNASDAQ
Loading
Latest News
globenewswire.com
Kestra Medical Technologies Reports Third Quarter Fiscal 2026 Financial Results
KIRKLAND, Wash., March 17, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today reported financial results for the third quarter fiscal 2026, which ended January 31, 2026.
globenewswire.com
Kestra Medical Technologies to Report Third Quarter Fiscal 2026 Financial Results on March 17
KIRKLAND, Wash., March 03, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today announced that it will report third quarter fiscal 2026 financial results on Tuesday, March 17. Management will host a corresponding conference call at 4:30 p.m. Eastern Time.
defenseworld.net
Kestra Medical Technologies (NASDAQ:KMTS) Insider Brian Daniel Webster Sells 15,000 Shares
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS - Get Free Report) insider Brian Daniel Webster sold 15,000 shares of the firm's stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $22.80, for a total value of $342,000.00. Following the sale, the insider owned 394,786 shares in the company, valued
defenseworld.net
Short Interest in Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Rises By 21.5%
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS - Get Free Report) was the target of a significant increase in short interest during the month of December. As of December 31st, there was short interest totaling 2,413,847 shares, an increase of 21.5% from the December 15th total of 1,986,266 shares. Currently, 4.3% of the shares of the company
zacks.com
KMTS, Biobeat Partner to Expand Diagnostic Insight in Cardiac Recovery
Kestra teams up with Biobeat in an exclusive deal, investing $5M to add continuous blood pressure monitoring to the ASSURE WCD during cardiac recovery.
seekingalpha.com
Kestra Medical Technologies, Ltd. (KMTS) Presents at 44th Annual J.P.
Kestra Medical Technologies, Ltd. (KMTS) Presents at 44th Annual J.P.
globenewswire.com
Kestra Medical Technologies Announces Strategic Collaboration with Biobeat Technologies to Expand Diagnostic Insight for Wearable Defibrillator Patients During Cardiac Recovery
KIRKLAND, Wash., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd.
defenseworld.net
Kestra Medical Technologies (NASDAQ:KMTS) Stock Price Down 6.1% – Here’s Why
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS - Get Free Report) was down 6.1% during trading on Friday. The stock traded as low as $24.89 and last traded at $24.89. Approximately 49,243 shares traded hands during mid-day trading, a decline of 83% from the average daily volume of 289,819 shares. The stock had previously closed at
defenseworld.net
Brian Daniel Webster Sells 15,000 Shares of Kestra Medical Technologies (NASDAQ:KMTS) Stock
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS - Get Free Report) insider Brian Daniel Webster sold 15,000 shares of the stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $26.59, for a total value of $398,850.00. Following the transaction, the insider directly owned 409,786 shares in the company, valued
defenseworld.net
Traci Umberger Sells 10,500 Shares of Kestra Medical Technologies (NASDAQ:KMTS) Stock
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS - Get Free Report) insider Traci Umberger sold 10,500 shares of the business's stock in a transaction that occurred on Monday, December 29th. The stock was sold at an average price of $26.69, for a total value of $280,245.00. Following the sale, the insider directly owned 136,633 shares in the
defenseworld.net
Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Shares of Kestra Medical Technologies, Ltd. (NASDAQ: KMTS - Get Free Report) have earned a consensus rating of "Moderate Buy" from the eight brokerages that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have assigned a buy
globenewswire.com
Kestra Medical Technologies to Present at the 44th Annual J.P. Morgan Healthcare Conference
KIRKLAND, Wash., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13 at 2:15 p.m. Pacific Time.
seekingalpha.com
Kestra Medical Technologies, Ltd. (KMTS) Q2 2026 Earnings Call Transcript
Kestra Medical Technologies, Ltd. (KMTS) Q2 2026 Earnings Call Transcript
globenewswire.com
Kestra Medical Technologies Reports Second Quarter Fiscal 2026 Financial Results
KIRKLAND, Wash., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today reported financial results for the second quarter fiscal 2026, which ended October 31, 2025.
globenewswire.com
Kestra Medical Technologies, Ltd. to Report Second Quarter Fiscal 2026 Financial Results
KIRKLAND, Wash., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd.
globenewswire.com
Kestra Medical Technologies, Ltd. Announces Pricing of Upsized Primary Public Offering of Common Shares
KIRKLAND, Wash., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd.
globenewswire.com
Kestra Medical Technologies, Ltd. Announces Primary Public Offering of Common Shares
KIRKLAND, Wash., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced an underwritten public offering of 5,500,000 common shares. Kestra is offering these shares pursuant to a registration statement on Form S-1 filed with the Securities and Exchange Commission (“SEC”). Kestra also intends to grant the underwriters a 30-day option to purchase up to an additional 825,000 common shares at the public offering price, less underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurances as to whether or when the offering may be completed or as to the actual size or terms of the offering. Kestra intends to use the proceeds to support sales and marketing activities, to drive ongoing commercialization, to further fund our research and development and clinical studies and for working capital and general corporate purposes. All of the common shares are being offered by Kestra.
globenewswire.com
Kestra Medical Technologies Reports Preliminary Second Quarter Fiscal 2026 Financial Results
KIRKLAND, Wash., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today reported preliminary financial results for the second quarter fiscal 2026 ended October 31, 2025.
globenewswire.com
Largest Real-World Study of Wearable Defibrillators Confirms Strong Effectiveness and Safety Performance of Kestra's ASSURE Device
KIRKLAND, Wash., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced primary results from the ASSURE® WCD Clinical Evaluation Post-Approval Study (ACE-PAS), presented as a late-breaking science session at the American Heart Association (AHA) Scientific Sessions 2025 in New Orleans. ACE-PAS, the largest prospective real-world study of wearable defibrillators to date, confirmed the strong safety and effectiveness of the ASSURE WCD in clinical practice.